Nasal Polyps

The AJMC® Nasal Polyps compendium is a comprehensive resource for clinical news and expert insights for the condition, which is caused by chronic inflammation.

Examining Biologic-Related Adverse Events in CRS With Nasal Polyps

September 23rd 2022, 6:10pm


Headaches, injection site reactions, and pharyngitis were the most common adverse events associated with the biologic therapies dupilumab, omalizumab, mepolizumab, and reslizumab in the treatment of chronic rhinosinusitis (CRS) with nasal polyps.

Risk Factors for CRS Plus Asthma Differ Among Younger vs Older Patients

September 14th 2022, 12:00pm


Risk factors as predictors of asthma prevalence among a cohort of patients living with chronic rhinosinusitis (CRS), as they related to age, were evaluated by clinical investigators from the College of Medicine at Korea University.

SCS Use May Predispose Patients Who Have CRSwNP to Worse Health Outcomes

September 9th 2022, 10:08pm


Using systemic corticosteroids (SCS) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) has been linked to adverse outcomes among patients, prompting these study investigators to compare their health care resource utilization with that of patients who have CRSwNP but don’t use SCS.

Bradykinin Level Displays Biomarker Benefit in Nasal Polyposis

August 30th 2022, 8:44pm


With evidence lacking on the role of inflammation in nasal polyposis (NP), this study investigated the role of 2 potential biomarkers in the nasal secretions of patients who have NP concomitant with aspirin-exacerbated respiratory disease.

Combination Treatment Provides Short-term Endoscopic Relief in CRSwNP Subtype

August 25th 2022, 9:12pm


This study investigated combination treatment of antibiotics plus corticosteroids among persons with aspirin-exacerbated respiratory disease, a subtype of chronic rhinosinusitis with nasal polyposis (CRSwNP).

Adherence to INC Treatment for Nasal Polyposis Remains Low

August 18th 2022, 6:51pm


Despite intranasal corticosteroid (INCs) being a treatment mainstay for chronic rhinosinusitis with nasal polyps, there are ongoing high rates of nonadherence, which can affect treatment efficacy, according to this study’s authors.

B7-H4 Identified as Potential Biomarker for CRSwNP in New Study

August 6th 2022, 7:15pm


This study investigated the potential for postoperative recurrence of chronic rhinosinusitis with nasal polyps (CRSwNP) as measured against B7-H4 expression.

Further Study Needed to Evaluate Olfaction Recovery in CRSwNP

August 3rd 2022, 6:04pm


This new study evaluated outcomes following add-on dupilumab to treat severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

Researchers Find Strong Overlap of Upper Airway Diseases

July 28th 2022, 6:47pm


There was also an association between outpatient visit burden and comorbidities and the number of inflammatory upper airway diseases.

Novel Model Appears Effective at Predicting ECRSwNP

July 20th 2022, 5:34pm


This new study investigated the ability of a multiparametric model to calculate risk of eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) by comparing its clinical characteristics with noneosinophilic CRSwNP.